Lung cancer is one of the most deadly disease and is responsible for many deaths each year. There are two major types of lung cancer: small cell and non-small cell lung cancer….
Tag: Lung Cancer Treatment
Lurbinectedin Combination gets FDA Approval for Extensive-Stage SCLC
The U.S. Food and Drug Administration (FDA) has approved lurbinectedin (Zepzelca) in combination with atezolizumab or and hyaluronidase-tqjs for adults with extensive-stage small cell lung cancer (ES-SCLC) without disease progression after frontline…
FDA Grants Breakthrough Therapy to Olomorasib to Treat Lung Cancer
Eli Lilly and Company has announced that US Food and Drug Administration (FDA) has granted breakthrough therapy designation to olomorasib, in combination with anti-PD1 therapy Keytruda for first-line treatment of patients with…
FDA Approves Hernexeos for HER2-Mutant Advanced Lung Cancer
For the first time, FDA has given approval of an oral treatment of patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have human epidermal growth factor receptor 2…
High-Dose Aumoltertinib for Untreated EGFR- Variant NSCLC
Aumoltertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and has achieved potent efficacy for advanced EGFR-mutated non-small cell lung cancer patients. Phase 2 non-randomized clinical trial was conducted at…
Tarlatamab Shows Improved Overall Survival Over Chemotherapy in SCLC
Tarlatamab received accelerated approval for treatment of patients with previously treated small-cell lung cancer. It meaningfully improved overall survival compared with Chemotherapy in SCLC patients that progressed on or after initial platinum-based…
FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC
The FDA has granted accelerated approval to Telisotuzumab vedotin for the treatment of patients with locally advanced or metastatic, nonsquamous non-small cell lung cancer with high c-MET protein overexpression. This approval is…
Heart-Sparing Technique in Lung Cancer Radiotherapy
A new study has been presented at ESTRO 2025 introducing RAPID-RT study. It utilizes an innovative rapid-learning approach to evaluate the impact of treatment modifications in radiotherapy. It offers a more inclusive…